Johnson & Johnson (NYSE:JNJ) Trades 0.8% Higher

Johnson & Johnson (NYSE:JNJ – Get Free Report ) stock price rose 0.8% on Friday. The stock traded as high as $162.92 and last traded at $162.67. About 615,748 shares traded hands during trading, down 91% from the average daily volume of 7,109,610 shares. Shares previously closed at $161.39.

The Wall Street analyst weighs in

A number of research firms have weighed in on JNJ. TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, the 23rd July. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Friday, September 20th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Moderate Buy” and an average target price of $173.21, according to MarketBeat .

Read our latest analysis of Johnson & Johnson

Johnson & Johnson price performance

The company has a market cap of $391.21 billion, a P/E ratio of 10.14, a price-to-earnings-growth ratio of 2.69 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85. The company’s 50-day moving average is $162.02 and its 200-day moving average is $154.27.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period last year, the firm posted EPS of $2.80. The company’s revenue rose 4.3% year-on-year. analysts predict that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 3.05%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider buying and selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. 0.16% of shares are currently owned by company insiders.

Johnson & Johnson Institutional Trading

Hedge funds have recently made changes to their business positions. Inçalta Capital LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $27,000. MFA Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the second quarter valued at $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $44,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $46,000. Finally, Grayhawk Investment Strategies Inc. raised its holdings in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares in the last quarter. 69.55% of the shares are currently held by hedge funds and other institutional investors.

About Johnson & Johnson

(Get a free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Featured stories

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.